-
Australian lawmaker 'critically' hurt in attack, officials say
-
'Physical hell': Hong Kong hosts gruelling underwater hockey tournament
-
Indonesia fires burned over 1.9 mn hectares through September: monitor
-
Police 'lost control' during French protests, says interior minister
-
Asian tech stocks mixed after Wall St losses, eyes on earnings
-
Australia's new Ghost Shark submarines grow some 'teeth'
-
China's third-quarter growth narrowly beats forecasts
-
'I call it a bribe': Pennsylvania residents spurn $10,000 data center checks
-
Asian stocks start week on back foot, tracking tech-led Wall St losses
-
In a former US steel city, ordinary people struggle to get by
-
China growth narrowly beats forecasts
-
'Liar,' 'clown': Lula and Bolsonaro spar in Brazil poll debate
-
Faith and fury: Texas Senate rivals offer contrasting visions
-
Record El Nino? Depends who's counting
-
Women await justice for police killings in Brazil
-
On the front line of ocean conservation off Portugal's Madeira
-
The painstaking task of cataloguing the world's species
-
Wembanyama targets title breakthrough as NBA season tips off
-
Nations seek reset at UN talks as nature goals off track
-
With LeBron on board it's title or bust for Philly fans
-
Rubio seeks to strengthen US foothold in Central Asia
-
One year after Louvre heist, where are the missing jewels?
-
LeBron joins 76ers to chase one more NBA title at age 41
-
Knicks face tall task in NBA championship repeat bid
-
Rays one win from World Series return after downing Guardians
-
Warriors' Curry 'fine' after limping out of practice - Kerr
-
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - October 19
-
Caledonia Mining Corporation Plc: Notification of Relevant Change To Significant Shareholder
-
Hemogenyx Pharmaceuticals PLC Announces Feasibility Study Agreement
-
Kings' Ben Simmons tears Achilles in training
-
Zelensky speaks to US envoys as Trump lashes out
-
Lula, Bolsonaro set for first debate showdown in bitter election race
-
'Surprise package' Lazio crush Juve to keep pace with Serie A leaders Inter
-
Mbappe hits two as Real Madrid rout Sevilla
-
China growth expected to miss official target in third quarter
-
Browns edge Ravens for division lead, Texans beat Jags
-
Lazio crush Juventus to move level with Serie A leaders Inter
-
Lyon go top of Ligue 1 as Monaco fall to first defeat of the season
-
Leeds draw feels like 'fresh start' for Man Utd's Carrick
-
Venezuela opposition alliance reaffirms Nobel laureate Machado as leader
-
Macron denounces 'unbridled' violence as France hit by new clashes
-
'Street Fighter' wins N. America box office, buzzy doc stuns in 2nd
-
Hurzeler lauds 'hard worker' Gomez after Brighton goal from halfway line
-
NFL: Paris game to go ahead despite protests in France
-
Toulouse hold off Exeter, Northampton save English Champions Cup blushes
-
Arteta hails Arsenal 'finishers' after Madueke fells Forest
-
Arsenal snatch late win to keep pressure on Man City as Man Utd held
-
Trump backs ally Netanyahu ahead of Israel's tight election
-
Arsenal strike late to keep pressure on Man City as Man Utd held
iFabric Corp. Announces 1,000 Store Expansion of Doctor's Choice(R) Scrubs at U.S. National Retailer
MARKHAM, ON / ACCESS Newswire / March 4, 2026 / iFabric Corp. ("iFabric" or the "Company") (TSX:IFA)(OTCQX:IFABF) is pleased to announce that its wholly-owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"), has secured a 1,000‑store expansion of Doctor's Choice® scrubs at a leading U.S. national big‑box retailer. This expansion significantly broadens in‑store access to Doctor's Choice® scrubs following the program's initial rollout, which began online and progressed into stores during late 2025.
The Company believes this expanded footprint reflects the retailer's confidence in the Doctor's Choice® scrubs program and validates both the strong consumer acceptance of the brand and the performance benefits delivered by the IFTNA proprietary textile technologies integrated into the collection.
"An expansion of this magnitude is a tremendous milestone for Doctor's Choice® scrubs and for IFTNA," said Giancarlo Beevis, President & CEO of IFTNA. "A move to an additional 1,000 stores is a clear signal that the retailer believes in the product, the brand, and-most importantly-the differentiated performance story our technologies deliver to healthcare professionals every day," added Mr. Beevis.
Doctor's Choice® technology enhanced scrubs were developed to combine comfort, durability, and practical clinical features with IFTNA's performance finishes. The current Doctor's Choice® scrub platforms integrate multiple IFTNA technologies, including:
PROTX2® (Advanced Antimicrobial) combined with ecoPEL™ (Durable Water Repellency)
PROTX2® (Advanced Antimicrobial) combined with DryTX™ (Moisture Management)
PROTX2® and ecoPEL™ have been supported by IFTNA's recently announced peer‑reviewed clinical trial results, which demonstrated statistically significant reductions in surface bacterial contamination on treated scrubs worn in real‑world healthcare environments compared to untreated scrubs. The published trial results can be found at:
https://www.journalofhospitalinfection.com/article/S0195-6701(25)00222-1/fulltext
"Healthcare professionals have been waiting a long time for medical textiles that don't just claim performance-but are supported by real clinical evidence," continued Mr. Beevis. "We believe there is pent‑up demand across the medical community for apparel that can offer an added layer of protection for professionals and their patients. The rapid expansion of Doctor's Choice® scrubs strongly reinforces that demand and the end-user acceptance of this game‑changing and clinically-validated technology," concluded Giancarlo Beevis.
The Doctor's Choice® scrub assortment is available both online and through the retailer's expanding store network. Consumers can view the Doctor's Choice® collection online at:
https://www.walmart.com/brand/doctorschoice/10004621
About iFabric Corp.
iFabric Corp. (TSX:IFA)(OTCQX:IFABF) develops, licenses, and commercializes innovative performance technologies for textiles and apparel. Through its Intelligent Fabric Technologies (North America) division, iFabric partners with global brands and retailers to deliver enhanced fabric functionality-ranging from antimicrobial technologies to moisture management and PFAS‑free water repellency-across diverse end uses. For more information, visit www.ifabriccorp.com.
About IFTNA
Intelligent Fabric Technologies (North America) Inc., a wholly owned subsidiary of iFabric Corp., engineers and supplies proprietary textile chemistries-including PROTX2®, ecoPEL™, and DryTX™-and provides end‑to‑end program capabilities spanning technology integration, product development, branding support, and manufacturing execution across consumer, medical, and industrial markets.
About PROTX2®
PROTX2® is an eco‑friendly textile technology designed to provide antimicrobial and anti‑odour protection. When applied, PROTX2® is engineered to deliver durable performance intended to last through the life of the garment.
About ecoPEL™
ecoPEL™ is a fluorine‑free durable water repellent ("DWR") technology designed to help deliver water repellency while maintaining fabric comfort and breathability, and to support sustainability objectives by avoiding fluorinated chemistry.
About DryTX™
DryTX™ is a moisture‑management technology designed to help improve comfort through wicking and quick‑dry properties.
Forward‑Looking Statements
This news release contains forward‑looking statements within the meaning of applicable securities laws, including statements regarding the scope and timing of store expansion, market adoption, future distribution, and anticipated performance attributes of products. Forward‑looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. iFabric undertakes no obligation to update forward‑looking statements except as required by applicable law.
FOR FURTHER INFORMATION PLEASE CONTACT:
Hylton Karon, President & CEO
Tel: 647.297.9815
Email: [email protected]
Giancarlo Beevis, COO
Tel: 647.225.4426
Email: [email protected]
Hilton Price, CFO
Tel: 647.465.6161
Email: [email protected]
Website: www.ifabriccorp.com
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Copyright © 2026 iFabric Corp.
iFabric™, PROTX2®, ecoPEL™, and DryTX™ are trademarks of iFabric Corp.
Doctor's Choice® is a third‑party trademark used under license.
SOURCE: iFabric Corp
View the original press release on ACCESS Newswire
R.Garcia--AT